10-Q · November 12, 2025
Lyra reported Q3 collaboration revenue of $25,000 and a net loss of $5.98 million (EPS -$3.38), an improvement versus Q3 2024 net loss of $11.87 million (EPS -$9.07). Operating expenses fell to $6.26 million from $12.64…
Earnings analysis · 10-K
LYRA earnings analysis
Filed March 31, 2026 · Our reading of the company's report
The latest report
Lyra suspended development of its lead candidate LYR-210 on January 9, 2026 and began a strategic review while implementing cost reductions and workforce cuts, after mixed clinical readouts (ENLIGHTEN 2 positive on June…
Read full summary
Lyra suspended development of its lead candidate LYR-210 on January 9, 2026 and began a strategic review while implementing cost reductions and workforce cuts, after mixed clinical readouts (ENLIGHTEN 2 positive on June 2, 2025; ENLIGHTEN 1 missed primary endpoint in May 2024). Revenue fell materially from approximately $1,534,000 in 2024 to $398,000 in 2025, the company faces ongoing cash burn and substantial doubt about its ability to continue as a going concern, and Nasdaq initiated delisting procedures in March 2026. The asset base includes a sizeable IP estate (21 U.S. issued patents and 53 foreign issued patents) and clinically significant ENLIGHTEN 2 results, but near-term prospects depend on obtaining substantial additional funding or completing a strategic transaction.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Gross margin
- 100.0%
What stood out
-
ENLIGHTEN 2 Phase 3: statistically significant primary result
On June 2, 2025 ENLIGHTEN 2 met its primary endpoint: 3CS at week 24 in patients without nasal polyps improved -1.13 (p=0.0078), and the full population 3CS improved -0.90 (p=0.0209) (filing).
-
Clinically meaningful symptom improvement (SNOT-22)
ENLIGHTEN 2 showed SNOT-22 improvement vs sham at week 24 of -8.7 (p=0.0101) and LYR-210 group change of -22.4 points from baseline at week 24 (filing).
-
Substantial patent estate with long coverage
As of December 31, 2025 the company reported owning 21 issued U.S. patents and 53 foreign issued patents, with coverage through at least 2030 and many patents through 2036–2038 (filing).
-
Material cost reductions executed
Following the May 2024 ENLIGHTEN 1 topline miss, the company reduced workforce by approximately 75% (impacting 87 employees) and paused manufacturing; in January 2026 it announced additional workforce reductions impacting 25 employees to preserve capital (filing).
What to watch
-
Suspension of LYR-210 development
On January 9, 2026 the Board approved suspension of further development of LYR-210 and a cost reduction plan (effective January 12, 2026) that includes a workforce reduction impacting substantially all remaining employees (filing).
-
Nasdaq delisting and trading suspension
Nasdaq notified the company on March 13, 2026 that it would commence delisting procedures; trading in the common stock was suspended at the open on March 17, 2026 (filing).
-
Additional pivotal trial required for NDA
Following a September 2025 meeting with the FDA, the company states an additional clinical trial is required for submission of an NDA for LYR-210, increasing funding needs (filing).
-
Material decline in revenue
Reported quarterly revenues show a drop from total 2024 revenue of $1,534,000 (532,000 + 598,000 + 195,000 + 209,000) to total 2025 revenue of $398,000 (183,000 + 183,000 + 25,000 + 7,000), indicating sharp top-line contraction (quarterly history).
-
Sustained cash burn / negative free cash flow
Quarterly free cash flow outflows were -$25M, -$20M, -$16M, and -$11M in 2024 (totaling -$72M) and at least -$7M, -$7M and -$6M in 2025 Q2–Q4 (Q1 2025 FCF not reported), demonstrating continued cash burn (quarterly history).
-
Going concern and need for significant funding
The filing states 'our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern' and that 'we need significant additional funding ... including the funding necessary to complete a third Phase 3 trial in LYR-210' (filing).
Management's outlook
No numeric annual guidance presented in the 10-K; management defers outlook to earnings press releases / strategic review. The MD&A discusses cash sufficiency concerns and that resumption of development would require a strategic transaction or significant additional funding (filing).
Earlier filings 4
10-Q · August 12, 2025
Lyra reported Q2 collaboration revenue of $183,000 and a net loss of $7.437 million (EPS -$5.51), a sharp operating and EPS improvement versus Q2 2024 losses. Operating expenses fell to $9.009 million from $49.572…
10-Q · May 6, 2025
Lyra reported Q1 collaboration revenue of $183,000 and GAAP net loss of $8.547 million (EPS -$0.13), an improvement versus Q1 2024 net loss of $22.452 million (EPS -$0.35). Management continues cost-reduction actions…
10-K · March 13, 2025
Lyra is a clinical-stage biotech focused on LYR-210 for chronic rhinosinusitis (CRS). The company reported a failed Phase 3 ENLIGHTEN 1 primary endpoint in May 2024, implemented a cost reduction including a reduction in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.